Immunotherapy for Tauopathies
Pathological tau protein is found in Alzheimer's disease and related tauopathies. The protein is hyperphosphorylated and/or mutated which leads to aggregation and neurotoxicity. Because cognitive functions correlate well with the degree of tau pathology, clearing these aggregates is a promising therapeutic approach. Studies pioneered by our laboratory and confirmed by others have shown that both active and passive immunizations targeting disease-related tau epitopes successfully reduce tau aggregates in vivo and slow or prevent behavioral impairments in mouse models of tauopathy. Here, we summarize recent advances in this new field.
KeywordsTau Tangles Immunization Immunotherapy Alzheimer's disease Tauopathies Mice
This study is supported by NIH grants AG032611, AG020197, the Alzheimer's Association, the Alzheimer's Drug Discovery Foundation/Association for Frontotemporal Dementia, and the Irma T Hirschl/Monique Caulier Trust.
Patent is pending on tau immunotherapy.
- Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. doi:10.1111/j.1471-4159.2011.07337.x
- Castillo DL, Lasagna-Reeves C, Guerrero-Munoz MJ, Estes DM, Barrett A, Dineley K, Jackson GR, Kayed R (2010) Modulation of tau oligomers by passive vaccination. Soc Neurosci Abstr 347.11Google Scholar
- Higuchi M (2011) Molecular mediators of amyloidosis-inflammation coupling in Alzheimer's disease: in vivo evidence in humans and animal models. Neurodegener Dis, 8(Suppl 1)Google Scholar
- Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR (2008) Long-term effects of Aβ(42) immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223PubMedCrossRefGoogle Scholar
- Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979–982PubMedCrossRefGoogle Scholar
- Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul MM, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25:402–405PubMedCrossRefGoogle Scholar
- Morgan D, Lee D, Brownlow M, Selenica M-L, Reid P, Alvarez J, Gordon MN (2011) Opposing roles of microglial activation in amyloid depositing and tau depositing transgenic mice. Neurodegener Dis, 8(Suppl 1)Google Scholar
- Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, van der Auwera I, van Leuven F, Sugawara M, Weingertner MC, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C (2007) Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 104:9810–9815PubMedCrossRefGoogle Scholar
- Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, Sesma T, Catena S, Sanchez B, Nieto M, Gomez-Ramos P, Moran MA, Cabodevilla F, Samaranch L, Ortiz L, Perez A, Ferrer I, Avila J, Gomez-Isla T (2005) Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 20:814–822PubMedCrossRefGoogle Scholar
- Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169:599–616PubMedCrossRefGoogle Scholar
- Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, DeMattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33:67–73PubMedCrossRefGoogle Scholar
- Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J Neurosci 24:6277–6282PubMedCrossRefGoogle Scholar
- Theunis C, Crespo Biel N, Borghgraef P, Devijver H, Gafner V, Philgren M, Hickman DT, Chuard N, Lopez Deber MP, Reis P, Buccarello AL, Adolfsson O, Pfeifer A, Muhs A, Van Leuven F (2011) Protein tau, target for immunotherapy: pre-clinical evaluation in transgenic mice. Neurodegener Dis, 8(Suppl 1)Google Scholar
- Troquier L, Burnouf S, Belarbi K, Caillierez R, Blum D, Buee L (2011) Modulation of tau pathology in THY-Tau22 transgenic mice: from physical exercise to immunotherapy. Neurodegener Dis, 8(Suppl 1)Google Scholar